Leyden Labs

Leyden Labs

Private
Amsterdam, North HollandHealthcare & Life Scienceshttps://www.leydenlabs.com

Last Round

Growth Equity

Oct 2, 2025

Total Funding Raised

$315.94M

Company Overview

Leyden Labs is a biotechnology company that develops intranasal products aimed at liberating humanity from respiratory viruses by providing broad-spectrum protection against multiple viral strains simultaneously.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

intranasal sprayPanFlumonoclonal antibodiespandemic preparednessnasal spraypassive immunitypan-influenza prophylacticrespiratory virus protectionmucosal protectionantibody therapyinfluenza protectionflu nasal sprayantibody nasal sprayuniversal flu protectioncoronavirus protectionclinical-stage biotechnologynasal deliverygovernment contracts

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Leyden Labs Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Leyden Labs Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Growth EquityOct 2, 2025
DebtJun 3, 2025
Series BJan 9, 2025
Series AMar 25, 2021

Key People

Founding team and executive leadership

Koenraad Wiedhaup

Founder And CEO

Founding Team

Marieke van der Lans

CFO, Chief Business Functions Officer

Executive Team

Leyden Labs Investors

Notable investors and investment history

InvestorRounds
GVSeries B, Series A
Invest-NLGrowth Equity
F-Prime CapitalSeries A, Series B
ClavystBioSeries B
SoftBank GroupSeries B
European Investment Bank GroupDebt
Bluebird VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 3, 2025

    $23.5M debt round completed.

  • Jan 9, 2025

    $70M round closed.

Leyden Labs Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Leyden Labs Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Leyden Labs's valuation, stock price, and market status.

Firmographic Details

HeadquartersAmsterdam, North Holland
Employee Range90
Year Founded2020
Last FundingOct 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.